Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech's 2009 Revenues Rise 81 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Osmetech today reported that its full-year 2009 revenues increased 81 percent, while the firm cut its net loss by 16 percent.

The British molecular diagnostics firm announced separately that has filed with the US Securities and Exchange Commission for an initial public offering of stock in the US under the name of its newly proposed parent, GenMark Diagnostics.

Osmetech's total revenues for the year were £638,186 ($961,753) compared to £352,069 for FY 2008. The firm said that the increase was due to growth in sales of its cystic fibrosis genotyping test and a warfarin sensitivity test. It added that currency translation accounted for 27 percent of the revenue growth.

Osmetech's net loss for 2009 dropped to £13 million, or 1.25 pence, from £15.5 million, or 6.66 pence.

The company said that its R&D expenses fell 33 percent to £1.8 million from £2.7 million, due primarily to the completion of development of its eSensor XT-8 System in 2008. It did not provide SG&S expenses.

Osmetech finished 2009 with £10.2 million in cash and cash equivalents.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.